ProCE Banner Series

Genetic Alterations in Unresectable and Metastatic Biliary Tract Cancer: The Evolution of Targeted Therapy

Join us for this case-based, interactive, CME-certified webinar featuring expert perspectives on molecular testing and targeted therapy for patients with advanced biliary tract cancers. Bring your questions for the live question and answer session with the expert panel.

  AMA
Who Should Attend

This program is intended for gastrointestinal oncologists involved in the diagnosis and management of patients with biliary tract cancer who are candidates for targeted systemic therapy.

All Events

Genetic Alterations in Unresectable and Metastatic Biliary Tract Cancer: The Evolution of Targeted Therapy

Past Events

March

19

2024

6:00 PM - 7:30 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

ProCE Banner Faculty
Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, confidence, and competence of the molecular testing for and therapeutic management of biliary tract cancer in patients that are candidates for targeted systemic therapy.

Target Audience
This program is intended for gastrointestinal oncologists involved in the diagnosis and management of patients with biliary tract cancer who are candidates for targeted systemic therapy.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Provide a detailed description of the known genomic alterations in BTC, the differences in their anatomical distribution and frequency, and their impact on disease progression
  • Select the appropriate molecular testing for individual patients with BTC and suspected genomic alterations, and explain the significance of the testing results to patients and their caregivers
  • Choose an appropriate targeted therapy based on the results of molecular testing for genomic alterations, and consider enrolling patients in clinical trials for alterations without an approved or off-label treatment option    

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.